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MKP-1 EXPRESSION AND DECREASINGP38
PHOSPHORYLATION
R. Nieminen1, R. Korhonen1, T. Moilanen2, A.R. Clark3,
E. Moilanen1
1Med. Sch., University of Tampere, Finland; 2Coxa Hosp. for Joint
Replacement, Tampere, Finland; 3The Kennedy Inst. of
Rheumatology Div., Imperial Coll., London, United Kingdom
Purpose: Aurothiomalate is a disease modifying antirheumatic
drug that suppresses inﬂammation and retards cartilage degrada-
tion and bone erosion in arthritis. The molecular mechanisms of
action of aurothiomalate are not known in detail. Mitogen-activated
protein kinase (MAPK) pathways are major signaling pathways in
inﬂammation, which regulate the production of many factors known
to mediate inﬂammation and cartilage destruction in OA and RA.
In the present study we investigated the effects of aurothiomalate
on the activity of p38 MAPK and expression of MAPK phosphatase
1 (MKP-1), COX-2, MMP-3 and IL-6 in chondrocytes and intact
cartilage.
Methods: Cartilage tissue was obtained from the leftover pieces
of total knee replacement surgery from patients with OA and RA
and from MKP-1-/- and wild type mice. Immortalized H4 murine
chondrocytes* were used in cell culture experiments.
Results: Aurothiomalate inhibited IL-1β -induced COX-2 expres-
sion and prostaglandin E2 (PGE2) production by destabilizing
COX-2 mRNA, as did the p38 MAPK inhibitor SB203580. Inter-
estingly, aurothiomalate also increased the expression of MKP-1
and reduced IL-1β -induced phosphorylation of p38 MAPK. Knock-
down of MKP-1 by siRNA signiﬁcantly impaired the ability of au-
rothiomalate to inhibit the phosphorylation of p38 MAPK and the
expression of COX-2, MMP-3 and IL-6. Likewise, aurothiomalate
reduced COX-2, MMP-3 and IL-6 expression in human rheuma-
toid arthritis (RA) and osteoarthritis (OA) cartilage, and in articular
cartilage from wild type mice but not in cartilage from MKP-1-/-
mice.
Conclusions: The results provide a novel mechanism for the anti-
inﬂammatory and anti-erosive action of aurothiomalate through
increased MKP-1 expression, reduced p38 MAPK activation and
suppressed expression of COX-2, MMP-3 and IL-6. MKP-1 may
therefore be a promising novel target for the development of
disease modifying drugs for RA and OA.
*Murine H4 chondrocyte cell line was kindly provided by Peter van
der Kraan, Laboratory of Experimental Rheumatology, University
Medical Center Nijmegen, Netherlands.
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Purpose: Over the past years hydrolyzed collagen has been used
in the treatment of OA and positive effects on joint health were
demonstrated in pre-clinical experiments and clinical studies. The
therapeutic mechanism, however, is still unknown.
The aim of this study was to investigate the inﬂuence of a
speciﬁc Collagen Hydrolysate (FORTIGEL®) on the proteoglycan
metabolism of the extracellular matrix (ECM) of chondrocytes.
Methods: Primary articular chondrocytes were isolated of porcine
ankle joint cartilage and cultured under reduced oxygen con-
ditions. The culture medium was supplemented with 0.5 mg
FORTIGEL®/ml according to recommended daily dose of pa-
tients. At different time points of the culture period the amount
of secreted and cell-associated proteoglycans (PGs) were quanti-
ﬁed by measuring 35S-sulphate incorporation. Total proteoglycan
biosynthesis was measured by speciﬁc staining of sulphate groups
with Alcian blue. Moreover, the expression of aggrecan was deter-
mined by Northern Blot analysis and the amount of aggrecan in
the ECM was analyzed via Western Blotting.
Results: Supplementation of the culture medium with FORTIGEL®
resulted in a statistically signiﬁcant (p<0.05) increase of total PG
synthesis. The amount of secreted and cell-associated PGs was
signiﬁcantly increased up to 1.6-fold after FORTIGEL® treatment
compared with the control cells. In particular, administration of
FORTIGEL® was associated with a statistically signiﬁcant increase
(p<0.05) of aggrecan biosynthesis shown by RNA expression and
accumulation of aggrecan intermediates and of native aggrecan in
the ECM as well.
Conclusions: These results indicate a stimulatory effect of
FORTIGEL® on the metabolism of proteoglycans in chondrocytes.
Thus FORTIGEL® may be helpful reducing degenerative changes
of the ECM by stimulating anabolic processes in cartilage tissue.
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THE EFFECTS OF DEOXYNIVALENOL, NIVALENOL, T-2
TOXIN AND SELENIUM SUPPLEMENTATION ON IN VITRO
TISSUE ENGINEERED CARTILAGE METABOLISM
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Kingdom
Purpose: To investigate the effects of Nivalenol (NIV), Deoxyni-
valenol (DON) and T-2 toxin, in the presence and absence of
Selenium (Se), on the metabolism of tissue engineered cartilage.
These in vitro cartilage cultures mimic those found in Kashin-
Beck Disease (KBD) environments that cause diarthrodial joint
degeneration in skeletal joint development and osteoarthritis with
ageing.
Methods: Bone matrix gelatin (BMG) was prepared from cancel-
lous bones of adult rabbits using previously published procedures
(Li et al. J Zhejiang Univ Sci B. 2008, 9(1): 22-33). Human chon-
drocytes were isolated from a 10th-week human embryo cartilage
anlagen by sequential enzyme treatments. One million Passage 2
cells were seeded onto BMG grafts for pre-culture for 48 hours.
Three toxins (DON, NIV & T-2 toxin), in the presence or absence
of Se, were added: DON, 1.0μg/ml; NIV, 0.1μg/ml; T-2, 0.01μg/ml;
Se, 0.1μg/ml. After 3 weeks culture in vitro, the BMG with the
tissue-engineered cartilage graft was ﬁxed, embedded, and cut
into 14μm slices for histological analysis. Slides were stained
with hematoxylin & eosin (H&E) and toluidine blue. Immunohisto-
chemical analysis was used to detect the expression of types II
& X collagen, aggrecan, MMP1, MMP3, TIMP1, TIMP3 and α2
macroglobulin.
Results: H&E staining showed that the tissue-engineered carti-
lage grafts were very similar to normal cartilage in vivo, with chon-
drocytes localised in lacunae, separated from each other by the
interterritorial extracellular matrix. There were no necrotic chon-
drocytes observed in the Control or the Toxin/Se treated groups.
Control tissue engineered cartilage grafts expressed aggrecan and
type II collagen, and a small amount of type X collagen. Immuno-
histochemical analysis of grafts exposed to DON, NIV and T-2
toxin showed decreased expression of type II collagen and aggre-
can. However, Se addition restored type II collagen and aggrecan
staining in the presence of these Toxins. There was increased
MMP-1 and MMP-3 expression in the Toxin-treated grafts. How-
